Fibrosis: Clinical Trials

310 completed, 90 unknown, 78 terminated, 69 recruiting. 618 Phase 2, 117 Phase 1, 75 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	618	Completed 310, Unknown 90, Terminated 78, Recruiting 69, Active not recruiting 25, Withdrawn 23, Not yet recruiting 17, Enrolling by invitation 3, Suspended 3
Phase 1	117	Completed 59, Unknown 26, Recruiting 11, Terminated 9, Withdrawn 5, Not yet recruiting 4, Active not recruiting 2, Suspended 1
Phase 3	75	Completed 34, Unknown 16, Recruiting 7, Terminated 7, Active not recruiting 4, Withdrawn 4, Not yet recruiting 2, Enrolling by invitation 1

Follow Fibrosis: new trials by email Literature Review of Fibrosis trials Research Report on Fibrosis

Trials (filtered) newest first · largest first

All 618 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Post-Operative Use of FS2 to Mitigate Scarring in Burn Patients IP1 control cream (Vehicle base), IP2 - 0.5% w/w FS2 - Burn Scar, Burn Wound	Phase 2 / Phase 3	Recruiting	Birch BioMed Inc	70	2027-03-01	2026-09-30
Phase II Clinical Study on Preliminary Efficacy and Safety of ETD-001 Gel for Hypertrophic Scars ETD-001 gel, Placebo - Hypertrophic Scars	Phase 2	Not yet recruiting	Etern Therapeutics Wuxi Limited	90	2027-02-28	2026-10-23
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD) ALN-CIDEB, Placebo - Alcohol-Associated Liver Disease, ALD	Phase 2	Not yet recruiting	Regeneron Pharmaceuticals	120	2026-12-09	2026-11-12
The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial Topical Timolol, Normal Saline - Surgical Wounds, Mohs Surgery	Phase 2	Not yet recruiting	Geisinger Clinic	45	2026-12-01	2026-10-14
Erlotinib for Hepatocellular Carcinoma Chemoprevention erlotinib hydrochloride, Placebo - Cirrhosis, Liver, Advanced Liver Fibrosis	Phase 2	Not yet recruiting	University of Texas Southwestern Medical Center	60	2026-12-01	2026-06-24
Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis Praziquantel 40 mg/kg per dose given once annually, Praziquantel 40 mg/kg given three times per year - Schistosomiasis, Schistosoma Mansoni	Phase 2 / Phase 3	Not yet recruiting	Rhode Island Hospital	600	2026-11-01	2026-08-12
Nemolizumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus Nemolizumab-ilto - Chronic Hepatic Pruritus, Cholestatic Liver Disease	Phase 2	Not yet recruiting	Mayo Clinic	15	2026-11-01	2026-09-28
Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE) Microbiota transplant therapy (MTT) capsules, Placebo capsule - Hepatic Encephalopathy, Cirrhosis	Phase 2	Not yet recruiting	VA Office of Research and Development	162	2026-10-30	2026-04-14
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia Foscenvivint - Liver Cirrhosis	Phase 2	Recruiting	Kiminori Kimura, MD	7	2026-10-01	2026-10-05
SCARFREE-001: Verteporfin for Scar Prevention Verteporfin Injection, Saline injection - Surgical Scar	Phase 2	Recruiting	Odense University Hospital	12	2026-10-01	2026-10-27
Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis Seladelpar, PTM Seladelpar, Cilofexor Dose B - Primary Biliary Cholangitis	Phase 2	Recruiting	Gilead Sciences	132	2026-10-01	2026-10-27
Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis Standard background therapy, Placebo, hUC-MSC Dose Level 1 - Primary Biliary Cholangitis	Phase 1 / Phase 2	Not yet recruiting	Beijing 302 Hospital	68	2026-08-31	2026-08-31
Study of Resmetirom in Children and Adolescents With MASH Resmetirom - MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis	Phase 2	Recruiting	Madrigal Pharmaceuticals, Inc.	61	2026-08-01	2026-09-11
FAPI PET Imaging - An Exploratory Study [18F]FAPI-74 PET/CT - Thyroid Pathology, Head and Neck Cancer (H&N)	Phase 1 / Phase 2	Not yet recruiting	Martin Huellner	770	2026-08-01	2026-07-15
A Clinical Study on the Safety and Efficacy of Wide-Band Ultrasound Combined With Traditional Chinese Medicine Preparations in the Prevention and Treatment of Keloids Wide-Band Ultrasound, traditional Chinese medicine - Keloid	Phase 1 / Phase 2	Not yet recruiting	Fujian Medical University Union Hospital	120	2026-08-01	2026-07-01
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) ALN-CIDEB, Placebo - Metabolic Dysfunction-Associated Steatohepatitis, MASH	Phase 2	Recruiting	Regeneron Pharmaceuticals	360	2026-07-06	2026-11-09
A-TANGO Phase 2 Study Placebo, TAK-242, G-CSF (Filgrastim) - Acute-On-Chronic Liver Failure, Alcoholic Hepatitis	Phase 2	Recruiting	Yaqrit Ltd	78	2026-06-29	2026-09-21
siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars Small interfering RNA (siRNA) Microneedle Patches, Carbon Dioxide (CO2) Laser Surgery, Intralesional Triamcinolone 40 mg/mL - Keloid of Ear Lobe	Phase 2	Not yet recruiting	Ong Kim Yao	158	2026-06-01	2026-07-06
TH104 for the Treatment of Pruritus in Primary Biliary Cholangitis Nalmefene, Placebo - Pruritus, Primary Biliary Cholangitis	Phase 2	Not yet recruiting	Tharimmune Inc	40	2026-06-01	2025-09-09
The Safety and Efficacy of Upadacitinib in Refractory Autoimmune Related Cholangitis and Atopic Dermatitis With Moderate to Severe Itching Upadacitinib 15 MG - Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC)	Phase 2	Not yet recruiting	RenJi Hospital	44	2026-06-01	2026-07-01

Showing 20 of 618. Sign in to see all of them.

Narrower conditions

Liver Cirrhosis (163)  ·  Pulmonary Fibrosis (85)  ·  Cicatrix (77)  ·  Liver Cirrhosis, Biliary (63)  ·  Non-alcoholic Fatty Liver Disease (47)  ·  Idiopathic Pulmonary Fibrosis (40)  ·  Hypertension, Portal (37)  ·  Keloid (37)  ·  Ascites (29)  ·  Cicatrix, Hypertrophic (27)  ·  Liver Diseases (26)  ·  Hepatitis C (25)  ·  Lung Diseases, Interstitial (24)  ·  Hepatic Encephalopathy (23)

Broader conditions

Pathological Conditions, Signs and Symptoms (618)  ·  Pathologic Processes (610)  ·  Digestive System Diseases (323)  ·  Liver Diseases (296)  ·  Respiratory Tract Diseases (94)  ·  Lung Diseases (85)  ·  Lung Diseases, Interstitial (71)  ·  Skin and Connective Tissue Diseases (71)  ·  Liver Cirrhosis (69)  ·  Bile Duct Diseases (64)  ·  Biliary Tract Diseases (63)  ·  Cholestasis, Intrahepatic (62)  ·  Cholestasis (60)  ·  Infections (52)

Interventions

TGFB3 protein, human (17)  ·  pirfenidone (14)  ·  Albumins (11)  ·  Saline Solution (10)  ·  Sodium Chloride (8)  ·  simtuzumab (8)  ·  3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid (7)  ·  Pentoxifylline (7)  ·  Rifaximin (7)  ·  Rituximab (7)  ·  Botulinum Toxins, Type A (6)  ·  Losartan (6)  ·  Midodrine (6)  ·  Ribavirin (6)  ·  Terlipressin (6)

Sponsors

Renovo (20)  ·  Gilead Sciences (17)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (15)  ·  Novartis Pharmaceuticals (7)  ·  Assistance Publique - Hôpitaux de Paris (6)  ·  AstraZeneca (6)  ·  Boehringer Ingelheim (6)  ·  Conatus Pharmaceuticals Inc. (6)  ·  Pfizer (6)  ·  Post Graduate Institute of Medical Education and Research, Chandigarh (6)  ·  Beijing 302 Hospital (5)  ·  Hospital Clinic of Barcelona (5)  ·  Intercept Pharmaceuticals (5)  ·  Mayo Clinic (5)  ·  National Heart, Lung, and Blood Institute (NHLBI) (5)

Countries

United States (290)  ·  United Kingdom (93)  ·  Canada (71)  ·  Spain (69)  ·  China (67)  ·  Germany (62)  ·  France (59)  ·  Italy (58)  ·  Belgium (40)  ·  Australia (37)  ·  Netherlands (28)  ·  South Korea (26)  ·  Argentina (23)  ·  Japan (22)  ·  Poland (22)

Top investigators

Jonathan Duncan (5)  ·  Daiming Fan (3)  ·  Jaime Bosch, MD (3)  ·  James Bush (3)  ·  Kiminori Kimura, MD (3)  ·  Pamela Pavco, PhD (3)  ·  Stephen Harrison, MD (3)

Results publications

PMID 19362676, PMID 39115183, PMID 25543678, PMID 28993537, PMID 29499740, PMID 29990488, PMID 33307033, PMID 33657443, PMID 36750244, PMID 37035316, PMID 38780109, PMID 40439725, PMID 10077078, PMID 10102814, PMID 10415784, PMID 11242330, PMID 11348456, PMID 11807470, PMID 12563677, PMID 12845617, PMID 12877429, PMID 14719037, PMID 15001284, PMID 15119583, PMID 15253184, PMID 15316341, PMID 15663512, PMID 15740535, PMID 16009415, PMID 16079683, PMID 16393283, PMID 16442954, PMID 16544259, PMID 16552809, PMID 16651948, PMID 16734808, PMID 16901024, PMID 16966752, PMID 16987047, PMID 17050868, PMID 17147494, PMID 17181919, PMID 17206944, PMID 17262225, PMID 17288322, PMID 17356110, PMID 17721093, PMID 17903050, PMID 18068515, PMID 18097874

NIH funding

2016 (11), 2023 (5), 2009 (4), 2015 (4), 2019 (4), 2025 (4), 2004 (2), 2005 (2), 2014 (2), 2017 (2), 2018 (2), P30CA060553 (2), 2008 (1), 272201800011C-P00005-9999-1 (1), I01CX002436 (1)